News >

FDA Grants Nivolumab Priority Review for SCLC

Jason M. Broderick @jasoncology
Published: Wednesday, Apr 18, 2018

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for nivolumab (Opdivo) for the treatment of patients with small cell lung cancer (SCLC) with disease progression following 2 or more lines of therapy, according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x